Komori
OncoTherapy Science (4564) · InitiativeRestated

Relocation of the head office and R&D facilities and improvement of operating efficiency and cost reduction

First written in FY2023-Q2. 2 of 4 entries say "Restated". Latest entry: FY2026-H1.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2023-Q3RestatedFY2025 – FY2026-H12022: 120222023: 120232024: 020242025: 22025
Same theme, other companies
Transfer and Streamlining of U.S. R&D and Administrative Operations to JapanA theme 2 companies write about · 1 as a headwind · 2 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「The company is also actively pursuing the relocation of its head office and research and development base and operational efficiency through the review of personnel assignments, and will continue to intensify its review and reduction of all costs.」

    Following the relocation of the head office and research and development base, the company continues to review personnel assignments, improve operational efficiency and reduce costs.
  2. FY2025RestatedAnnual report

    「The company is also actively pursuing the relocation of its head office and research and development base and operational efficiency through the review of personnel assignments, and will continue to intensify its review and reduction of all costs.」

    Following the relocation of the head office and research and development base, the company continues to review personnel assignments, improve operational efficiency and reduce costs.
  3. FY2023-Q3AdvancedAnnual report

    「The company relocated its head office and research and development base effective 1 January 2023, and will continue to intensify its review and reduction of all costs, including through greater operational efficiency achieved by reviewing personnel assignments.」

    The relocation of the head office and research and development base, which was described as a decision in FY2023-Q2, was implemented effective 1 January 2023, and the company moved into a phase of intensifying its review of personnel assignments, operational efficiency and cost reduction.
  4. FY2023-Q2First statedAnnual report

    「As announced on 28 October 2022, the company decided to relocate its head office and research and development base, and will continue to intensify its review and reduction of all costs, including through greater operational efficiency achieved by reviewing personnel assignments.」

    The company decided to relocate its head office and research and development base, and for the first time described measures to review personnel assignments, improve operational efficiency, and review and reduce costs.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.